Empowerment program for men with prostate cancer to improve mental health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to support men diagnosed with prostate cancer by implementing the Prostate Cancer Patient Empowerment Program (PC-PEP), which focuses on enhancing mental health and quality of life. The intervention includes education on life skills, physical activity, stress reduction, and social support, delivered through in-person and multimedia formats. The study will compare the outcomes of participants in the PC-PEP program against a control group receiving standard care, assessing their mental health and treatment-related side effects over a period of 24 months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18
* History of a prostate cancer diagnosis
* Safe to exercise and do strength training (participants who have recovered from a minor stroke or heart condition in the past will require approval from their Family Physician or Cardiologist to participate in the study. Participants with advanced prostate cancer will need approval from the Study Physician or their Urologist or Oncologist to participate)
* Existing (or willingness to create) email account
* Willingness to access and use daily email and/or text messages
* Ability to follow website links to watch YouTube videos
* Ability to understand and speak English
* Ability to participate in low to moderate levels of physical activity
* Ability and willingness to fill out an online survey at baseline, and 6, 12 and 24 months, and a weekly compliance survey for the six months of the program.
* Deemed to have an expected survival greater than 2 years

Exclusion Criteria:

* Patients deemed unfit to participate in low level exercise eg. including but not limited to a myocardial infarction or stroke within the last year, without approval from their Family Physician or Cardiologist that they are safe to exercise.
* Unable to access the internet and lack of a computer or cellphone to receive emails required for study intervention, or unable to click on a link to successfully watch a YouTube video.
* Men with a predicted survival less than 2 years.

Where it's running

• Dianne and Irving Kipnes Urology Centre
  Edmonton, Alberta, Canada Recruiting
• BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
  Kelowna, British Columbia, Canada Recruiting
• Men's Health Clinic Manitoba
  Winnipeg, Manitoba, Canada Recruiting
• Saint John Regional Hospital
  Saint John, New Brunswick, Canada Recruiting
• Health Sciences Centre
  St. John's, Newfoundland and Labrador, Canada Recruiting
• QEII Health Sciences Centre
  Halifax, Nova Scotia, Canada Recruiting

Study contacts

• Study coordinator: Gabriela Ilie, PhD
• Email: Gabriela.Ilie@dal.ca
• Phone: 902-989-4114

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.